Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Gains from Sales and Divestitures: 2024

Historic Gains from Sales and Divestitures for Cellebrite DI (CLBT) over the last 1 years, with Dec 2024 value amounting to $7.3 billion.

  • Cellebrite DI's Gains from Sales and Divestitures rose 273.74% to $6.4 billion in Q2 2025 from the same period last year, while for Jun 2025 it was $6.4 billion, marking a year-over-year increase of 273.74%. This contributed to the annual value of $7.3 billion for FY2024, which is N/A change from last year.
  • Cellebrite DI's Gains from Sales and Divestitures amounted to $7.3 billion in FY2024.
  • Cellebrite DI's Gains from Sales and Divestitures' 5-year high stood at $7.3 billion during FY2024, with a 5-year trough of $7.3 billion in FY2024.
  • For the 1-year period, Cellebrite DI's Gains from Sales and Divestitures averaged around $7.3 billion, with its median value being $7.3 billion (2024).